EGFR and neoplasm: Meanwhile, the immune scores and the expression immune checkpoint molecules in EGFR and TP53 mutant groups were obviously higher than those in wildtype, suggesting that EGFR and TP53 mutation may lead to the secretion of certain substances to activate the immune checkpoints, thus inhibiting the immune function of T cells, escaping immune monitoring and promoting tumour progression.